Open AccessPrediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
Author(s) -
Michitaka Imai,
Toru Ishikawa,
Yuichi Kojima,
Motoi Azumi,
Yoshinori Nozawa,
Tomoe Sano,
Akito Iwanaga,
Teruki Honma,
Toshiaki Yoshida
Publication year - 2020
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 102
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/meg.0000000000001985
Subject(s) - medicine , ascites , hepatocellular carcinoma , tolvaptan , gastroenterology , cirrhosis , proportional hazards model , univariate analysis , multivariate analysis , urology , hyponatremia
Tolvaptan (TVP) is an effective treatment for patients with cirrhotic ascites; however, studies have indicated that a sufficient effect is difficult to obtain in patients with hepatocellular carcinoma (HCC). This study evaluates the efficacy of TVP in patients with HCC with refractory ascites.